Point72 Asset Management
ALDX icon

Point72 Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Point72 Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94,094
Closed -$487K – 3737
2025
Q4 		$487K Buy
+94,094
New +$483K ﹤0.01% 3241
2023
Q2 		– Sell
-8,510
Closed -$84.5K – 2124
2023
Q1 		$84.5K Buy
+8,510
New +$60.2K ﹤0.01% 1668
2021
Q1 		– Sell
-858,270
Closed -$5.89M – 935
2020
Q4 		$5.89M Buy
858,270
+216,352
+34% +$1.52M 0.03% 552
2020
Q3 		$4.76M Buy
+641,918
New +$4.15M 0.02% 576
2019
Q3 		– Sell
-325,000
Closed -$1.95M – 1105
2019
Q2 		$1.95M Buy
+325,000
New +$2.45M 0.01% 656

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management's ALDX Position: Q1 2026 in Review

Point72 Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 94,094 shares — an estimated $487K sold.

Point72 Asset Management first reported a position in ALDX in Q2 2019 and held it in 5 quarters. The position peaked at $5.89M in Q4 2020. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Point72 Asset Management reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 94,094 Aldeyra Therapeutics shares in Q1 2026, an estimated $487K.
  • Point72 Asset Management first reported a position in Aldeyra Therapeutics in Q2 2019 and held it in 5 quarters.
  • Point72 Asset Management's Aldeyra Therapeutics position peaked at $5.89M in Q4 2020.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.